NCT05124340View on ClinicalTrials.gov

Safety and Tuberculin Conversion Following BCG Vaccination

PHASE2CompletedINTERVENTIONAL
Enrollment

220

Participants

Timeline

Start Date

December 1, 2021

Primary Completion Date

May 31, 2022

Study Completion Date

July 30, 2022

Conditions
BCG Vaccination Reaction
Interventions
BIOLOGICAL

BCG vial vaccine

Intradermal injection

BIOLOGICAL

BCG ampoule vaccine

Intradermal injection

Trial Locations (1)

Unknown

Puskesmas Cerme, Gresik

Sponsors

Lead Sponsor

PT Bio Farma
All Listed Sponsors
collaborator

Dr. Soetomo General Hospital

OTHER_GOV

lead

PT Bio Farma

INDUSTRY

NCT05124340 - Safety and Tuberculin Conversion Following BCG Vaccination | Biotech Hunter | Biotech Hunter